CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings....
Get updates from ProMIS Neurosciences, Inc. (PMN) Press Releases via email, on your phone or read them on follow.it on your own custom news page.
You can filter the news from ProMIS Neurosciences, Inc. (PMN) Press Releases that get delivered to you using tags or topics or you can opt for all of them. Unsubscription is also very simple.
See the latest news from ProMIS Neurosciences, Inc. (PMN) Press Releases below.
Site title: ProMIS Neurosciences, Inc. (PMN)